Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals 2024-11-04 06:07
Ping An Health Achieves WONCA International Quality Dual Certifications Defining New Standards in Internet Healthcare Services 2024-11-03 01:39
The 1-Year Follow-up Results of LuX-Valve Plus were Officially Released at TCT 2024 2024-11-01 21:00
DX&VX Selected for Korea's First ARPA-H Project in 2024, Focusing on Room Temperature and Extra-Long-Term Vaccine Storage Technology 2024-11-01 21:00
The clinical trial application for first-line treatment of extensive disease small cell lung cancer with Chiauranib has been approved 2024-11-01 19:04
HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update 2024-11-01 19:00
Senhwa Biosciences Announces the Appointment of Dr. Yiu-Lian Fong, the Former Global Head of Janssen Diagnostic Innovation and R&D at Johnson & Johnson as the New Corporate Director 2024-11-01 15:28
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab 2024-11-01 11:34
CARsgen® U.S. Clinical Holds Lifted by FDA 2024-11-01 09:33
Formosa Pharmaceuticals and DÁVI Farmacêutica Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain 2024-10-31 21:36
Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology 2024-10-31 20:00
I-Mab to Release Q3 2024 Financial Results on November 14, 2024 2024-10-31 19:00
ZYMFENTRA® (infliximab-dyyb) coverage continues to increase through partnership with top 3 Pharmacy Benefit Managers (PBMs) 2024-10-31 14:31
CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK 2024-10-31 13:00
Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLC 2024-10-31 12:34
Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLC 2024-10-31 12:02
Breakthrough Australian Cancer trial: retraining immune cells offers new hope for patients 2024-10-31 12:00
Abionic's CAPSULE PSP Receives FDA Approval for Early Detection of Sepsis; Fapon Introduces Exclusive PSP Solution in China via Licensing Collaboration 2024-10-31 10:26
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab 2024-10-31 08:46
Latest Updates of Viva Biotech's Portfolio Companies 2024-10-30 22:24
1 3 4 5 6 7 412